UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 10-Q

________________________

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 001-40860

________________________

Olaplex Holdings, Inc.

(Exact name of registrant as specified in its charter)

________________________


Delaware						87-1242679
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

Address not applicable1

(Address of principal executive offices and zip code)

(310) 691-0776

(Registrant’s telephone number, including area code)

________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

OLPX

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☒	Accelerated Filer	☐

Non-accelerated Filer	☐	Smaller reporting company	☐

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~May 5,~~August 4, 2023, registrant had ~~654,276,766~~654,698,308 shares of common stock, par value $0.001 per share, outstanding.

1 Olaplex Holdings, Inc. is a fully remote company. Accordingly, it does not maintain a principal executive office.

Table of Contents

OLAPLEX HOLDINGS, INC.

TABLE OF CONTENTS


		Page
Part I.	FINANCIAL INFORMATION
Item 1.	Financial Statements	5
	Condensed Consolidated Balance Sheets	5
	Condensed Consolidated Statements of Operations and Comprehensive Income	6
	Condensed Consolidated Statements of Changes in Equity	7
	Condensed Consolidated Statements of Cash Flows	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1617
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	2327
Item 4.	Controls and Procedures	2428
Part II.	OTHER INFORMATION
Item 1.	Legal Proceedings	2529
Item 1A.	Risk Factors	2529
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2529
Item 3.	Defaults Upon Senior Securities	2529
Item 4.	Mine Safety Disclosures	2529
Item 5.	Other Information	2529
Item 6.	Exhibits	2630
Signatures		2731

Table of Contents

GLOSSARY

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), the terms identified below have the meanings specified below unless otherwise noted or the context indicates otherwise. Except where the context otherwise requires or where otherwise indicated, the terms “OLAPLEX” “we,” “us,” “our,” “the Company,” and “our business” refer to Olaplex Holdings, Inc. and its consolidated subsidiaries.

•“2020 Credit Agreement” refers to the Credit Agreement, dated as of January 8, 2020, by and among Olaplex, Inc., Penelope Intermediate Corp., MidCap Financial Trust, as administrative agent, collateral agent and swingline lender, and each lender and issuing bank from time to time party thereto, as amended by the First Incremental Amendment to the 2020 Credit Agreement, dated as of December 18, 2020. The 2020 Credit Agreement was refinanced and replaced by the 2022 Credit Agreement.

•“2022 Credit Agreement” refers to the Credit Agreement, dated as of February 23, 2022, by and among Olaplex, Inc., Penelope Intermediate Corp, Goldman Sachs Bank USA, as administrative agent, collateral agent and swingline lender, and each lender and issuing bank from time to time party thereto. The 2022 Credit Agreement refinanced and replaced the 2020 Credit Agreement, and includes, among other things, a $675 million seven-year senior-secured term loan facility (the “2022 Term Loan Facility”) and a $150 million five-year senior-secured revolving credit facility (the “2022 Revolver”).

•“IPO” refers to the initial public offering of shares of common stock of Olaplex Holdings, Inc., completed on October 4, 2021.

•“Penelope” refers to Penelope Holdings Corp., which is an indirect parent of Olaplex, Inc., the Company’s primary operating subsidiary.

•“Penelope Group Holdings” refers to Penelope Group Holdings L.P., which prior to the IPO was the direct parent of Penelope.

•“Pre-IPO Stockholders” refers to, collectively, (i) the former limited partners of Penelope Group Holdings prior to the Reorganization Transactions and (ii) holders of options to purchase shares of common stock of Penelope that were vested as of the consummation of the Reorganization Transactions.

•“Pre-IPO Tax Assets” refers to, collectively, certain tax attributes existing prior to the IPO, including tax basis in intangible assets and capitalized transaction costs relating to taxable years ending on or before the date of the IPO (calculated by assuming the taxable year of the relevant entity closes on the date of the IPO), that are amortizable over a fixed period of time (including in tax periods beginning after the IPO) and which are available to us and our wholly-owned subsidiaries.

•“Reorganization Transactions” refers to the internal reorganization completed in connection with our IPO, pursuant to which Olaplex Holdings, Inc. became an indirect parent of Olaplex, Inc. For further information, see “Reorganization Transactions” in “Note 1 - Nature of Operations and Basis of Presentation” to our Consolidated Financial Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2022.

•“Tax Receivable Agreement” refers to the income tax receivable agreement entered into by the Company in connection with the Reorganization Transactions under which the Company is required to pay the Pre-IPO Stockholders 85% of the cash savings, if any, in United States (“U.S.”) federal, state or local tax that the Company actually realizes on its taxable income following the IPO, as specified in the Tax Receivable Agreement.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains certain forward-looking statements and information relating to us that are based on the beliefs of our management as well as assumptions made by, and information currently available to, us. These statements include, but are not limited to, statements about our strategies, plans, objectives, expectations, intentions, expenditures and assumptions and other statements contained in or incorporated by reference in this Quarterly Report that are not historical or current facts. When used in this document, words such as “may,” “will,” “could,” “should,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “forecast,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements.

The forward-looking statements in this Quarterly Report reflect our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operation. Examples of forward-looking statements include, among others, statements we make regarding: our financial position and operating results; our business plans, strategies and objectives, including sales and marketing investments; general economic and industry trends; our business prospects; our reputation and brand; our product technology; future product development and introduction, including entry into adjacent and other categories; growth and expansion opportunities, including expansion in existing markets and into new markets; our sales channels and omnichannel strategy; legal proceedings; future payments under our Tax Receivable Agreement; our customer base; our supply chain and global distribution network; our information technology; our employees and culture; our operational capabilities; interest rate derivatives; and our expenses, inventory levels, other working capital and liquidity. Forward-looking statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on our forward-looking statements. Neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.

Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation, the following:

•our ability to anticipate and respond to market trends and changes in consumer preferences and execute on our growth strategies and expansion opportunities, including with respect to new product introductions;

•our ability to develop, manufacture and effectively and profitably market and sell future products;

•our ability to accurately forecast customer and consumer demand for our products;

•competition in the beauty industry;

•our ability to effectively maintain and promote a positive brand image and expand our brand awareness;

•our dependence on a limited number of customers for a large portion of our net sales;

•our ability to attract new customers and consumers and encourage consumer spending across our product portfolio;

•our ability to successfully implement new or additional marketing efforts;

•our relationships with and the performance of our suppliers, manufacturers, distributors and retailers and our ability to manage our supply chain;

•impacts on our business from political, regulatory, economic, trade and other risks associated with operating internationally;

•our ability to attract and retain senior management and other qualified personnel;

•our reliance on our and our third-party service providers’ information technology;

•our ability to maintain the security of confidential information;

•our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others;

•the outcome of litigation and regulatory proceedings;

•the impact of changes in federal, state and international laws, regulations and administrative policy;

Table of Contents

•our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under the 2022 Credit Agreement;

~~Table of Contents~~

•our ability to service our existing indebtedness and obtain additional capital to finance operations and our growth opportunities;

•volatility of our stock price;

•our “controlled company” status and the influence of investment funds affiliated with Advent International Corporation over us;

•the impact of an economic downturn and inflationary pressures on our business;

•fluctuations in our quarterly results of operations;

•changes in our tax rates and our exposure to tax liability; and

•the other factors identified in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”) and in other documents that we file with the U.S. Securities and Exchange Commission from time to time.

Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this Quarterly Report as anticipated, believed, estimated, expected, intended, planned or projected. We discuss many of these risks in greater detail in the “Risk Factors” section of our 2022 Form 10-K. The forward-looking statements included in this Quarterly Report are made only as of the date hereof. Unless required by law, we neither intend nor assume any obligation to update these forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations or otherwise.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements

OLAPLEX HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except per share and share data)

(Unaudited)


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Assets	Assets					Assets
Current Assets:	Current Assets:					Current Assets:
Cash and cash equivalents	Cash and cash equivalents	$	369,340	$	322,808	Cash and cash equivalents	$	378,418	$	322,808
Accounts receivable, net of allowances of $17,499 and $19,198		45,516		46,220
Accounts receivable, net of allowances of $20,028 and $19,198						Accounts receivable, net of allowances of $20,028 and $19,198	50,298		46,220
Inventory	Inventory	132,014		144,425		Inventory	128,509		144,425
Other current assets	Other current assets	16,665		8,771		Other current assets	13,398		8,771
Total current assets	Total current assets	563,535		522,224		Total current assets	570,623		522,224
Property and equipment, net	Property and equipment, net	1,026		1,034		Property and equipment, net	932		1,034
Intangible assets, net	Intangible assets, net	982,962		995,028		Intangible assets, net	971,715		995,028
Goodwill	Goodwill	168,300		168,300		Goodwill	168,300		168,300

Other assets	Other assets	10,004		11,089		Other assets	11,354		11,089
Total assets	Total assets	$	1,725,827	$	1,697,675	Total assets	$	1,722,924	$	1,697,675

Liabilities and stockholders’ equity	Liabilities and stockholders’ equity					Liabilities and stockholders’ equity
Current Liabilities:	Current Liabilities:					Current Liabilities:
Accounts payable	Accounts payable	$	9,408	$	9,748	Accounts payable	$	13,666	$	9,748
Sales and income taxes payable		5,799		3,415
Sales and income taxes payable, net						Sales and income taxes payable, net	—		3,415
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	19,919		17,107		Accrued expenses and other current liabilities	24,649		17,107
Current portion of long-term debt	Current portion of long-term debt	6,750		8,438		Current portion of long-term debt	6,750		8,438
Current portion of Related Party payable pursuant to Tax Receivable Agreement	Current portion of Related Party payable pursuant to Tax Receivable Agreement	16,352		16,380		Current portion of Related Party payable pursuant to Tax Receivable Agreement	16,184		16,380
Total current liabilities	Total current liabilities	58,228		55,088		Total current liabilities	61,249		55,088
Long-term debt	Long-term debt	653,006		654,333		Long-term debt	651,678		654,333
Deferred tax liabilities	Deferred tax liabilities	2,301		1,622		Deferred tax liabilities	2,754		1,622
Related Party payable pursuant to Tax Receivable Agreement	Related Party payable pursuant to Tax Receivable Agreement	205,675		205,675		Related Party payable pursuant to Tax Receivable Agreement	189,391		205,675
Total liabilities	Total liabilities	919,210		916,718		Total liabilities	905,072		916,718

Contingencies (Note 10)	Contingencies (Note 10)					Contingencies (Note 10)

Stockholders’ equity (Notes 1 and 8):	Stockholders’ equity (Notes 1 and 8):					Stockholders’ equity (Notes 1 and 8):
Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 653,776,766 and 650,091,380 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		653		649
Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 654,530,828 and 650,091,380 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively						Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 654,530,828 and 650,091,380 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	654		649
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding	Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding	—		—		Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding	—		—
Additional paid-in capital	Additional paid-in capital	318,124		312,875		Additional paid-in capital	321,555		312,875
Accumulated other comprehensive income	Accumulated other comprehensive income	2,020		2,577		Accumulated other comprehensive income	3,667		2,577
Retained earnings	Retained earnings	485,820		464,856		Retained earnings	491,976		464,856
Total stockholders’ equity	Total stockholders’ equity	806,617		780,957		Total stockholders’ equity	817,852		780,957
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	1,725,827	$	1,697,675	Total liabilities and stockholders’ equity	$	1,722,924	$	1,697,675

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

Table of Contents

OLAPLEX HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(amounts in thousands, except per share and share data)

(Unaudited)


		Three Months Ended March 31,			Three Months Ended June 30,						Six Months Ended June 30,
			2023			2022			2023		2022		2023		2022
Net sales	Net sales		$	113,787		$	186,196	Net sales	$	109,241	$	210,903	$	223,028	$	397,099
Cost of sales:	Cost of sales:							Cost of sales:
Cost of product (excluding amortization)	Cost of product (excluding amortization)		31,235			43,222		Cost of product (excluding amortization)	29,781		52,293		61,016		95,515
Amortization of patented formulations	Amortization of patented formulations		1,742			1,769		Amortization of patented formulations	1,964		2,180		3,706		3,949
Total cost of sales	Total cost of sales		32,977			44,991		Total cost of sales	31,745		54,473		64,722		99,464
Gross profit	Gross profit		80,810			141,205		Gross profit	77,496		156,430		158,306		297,635
Operating expenses:	Operating expenses:							Operating expenses:
Selling, general, and administrative	Selling, general, and administrative		34,924			22,314		Selling, general, and administrative	48,413		26,111		83,337		48,425
Amortization of other intangible assets	Amortization of other intangible assets		10,323			10,266		Amortization of other intangible assets	10,324		10,295		20,647		20,561

Total operating expenses	Total operating expenses		45,247			32,580		Total operating expenses	58,737		36,406		103,984		68,986
Operating income	Operating income		35,563			108,625		Operating income	18,759		120,024		54,322		228,649
Interest expense, net	Interest expense, net		(10,543)			(11,460)		Interest expense, net	(10,206)		(8,694)		(20,749)		(20,154)
Other income (expense), net
Other expense, net								Other expense, net
Loss on extinguishment of debt	Loss on extinguishment of debt		—			(18,803)		Loss on extinguishment of debt	—		—		—		(18,803)
Other income (expense), net			242			(377)
Total other income (expense), net			242			(19,180)
Other expense, net								Other expense, net	(600)		(1,224)		(358)		(1,601)
Total other expense, net								Total other expense, net	(600)		(1,224)		(358)		(20,404)
Income before provision for income taxes	Income before provision for income taxes		25,262			77,985		Income before provision for income taxes	7,953		110,106		33,215		188,091
Income tax provision	Income tax provision		4,298			16,024		Income tax provision	1,797		22,391		6,095		38,415
Net income	Net income		$	20,964		$	61,961	Net income	$	6,156	$	87,715	$	27,120	$	149,676

Net income per share:	Net income per share:							Net income per share:
Basic	Basic		$	0.03		$	0.10	Basic	$	0.01	$	0.14	$	0.04	$	0.23
Diluted	Diluted		$	0.03		$	0.09	Diluted	$	0.01	$	0.13	$	0.04	$	0.22
Weighted average common shares outstanding:	Weighted average common shares outstanding:							Weighted average common shares outstanding:
Basic	Basic		651,730,993			648,813,998		Basic	654,345,056		648,973,952		653,045,245		648,894,417
Diluted	Diluted		683,485,182			693,021,097		Diluted	680,349,161		691,365,072		682,107,732		692,985,088

Other comprehensive loss:
Unrealized loss on derivatives, net of income tax effect			$	(557)		$	—
Total other comprehensive loss:			(557)			—
Other comprehensive income:								Other comprehensive income:
Unrealized gain on derivatives, net of income tax effect								Unrealized gain on derivatives, net of income tax effect	$	1,647	$	—	$	1,090	$	—
Total other comprehensive income:								Total other comprehensive income:	1,647		—		1,090		—
Comprehensive income:	Comprehensive income:		$	20,407		$	61,961	Comprehensive income:	$	7,803	$	87,715	$	28,210	$	149,676

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

Table of Contents

OLAPLEX HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(amounts in thousands, except number of shares)

(Unaudited)


		Shares (Note 1)	Amount		Additional Paid in Capital		Accumulated Other Comprehensive Income		Retained Earnings		Total Equity			Shares (Note 1)	Amount		Additional Paid in Capital		Accumulated Other Comprehensive Income		Retained Earnings		Total Equity
Balance - December 31, 2022	Balance - December 31, 2022	650,091,380	$	649	$	312,875	$	2,577	$	464,856	$	780,957	Balance - December 31, 2022	650,091,380	$	649	$	312,875	$	2,577	$	464,856	$	780,957
Net income	Net income	—	—		—		—		20,964		20,964		Net income	—	—		—		—		20,964		20,964
Exercise of stock-settled stock appreciation rights	Exercise of stock-settled stock appreciation rights	109,620	—		326		—		—		326		Exercise of stock-settled stock appreciation rights	109,620	—		326		—		—		326
Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	(83,501)	—		(390)		—		—		(390)		Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	(83,501)	—		(390)		—		—		(390)
Exercise of stock options	Exercise of stock options	3,659,267	4		3,295		—		—		3,299		Exercise of stock options	3,659,267	4		3,295		—		—		3,299
Share-based compensation expense	Share-based compensation expense	—	—		2,018		—		—		2,018		Share-based compensation expense	—	—		2,018		—		—		2,018
Unrealized loss on derivatives (net of taxes)	Unrealized loss on derivatives (net of taxes)	—	—		—		(557)		—		(557)		Unrealized loss on derivatives (net of taxes)	—	—		—		(557)		—		(557)
Balance – March 31, 2023	Balance – March 31, 2023	653,776,766	$	653	$	318,124	$	2,020	$	485,820	$	806,617	Balance – March 31, 2023	653,776,766	$	653	$	318,124	$	2,020	$	485,820	$	806,617
Net income													Net income	—	—		—		—		6,156		6,156
Exercise of stock options													Exercise of stock options	754,062	1		797		—		—		798
Share-based compensation expense													Share-based compensation expense	—	—		2,634		—		—		2,634
Unrealized gain on derivatives (net of taxes)													Unrealized gain on derivatives (net of taxes)	—	—		—		1,647		—		1,647
Balance – June 30, 2023													Balance – June 30, 2023	654,530,828	654		321,555		3,667		491,976		817,852


		Shares (Note 1)	Amount		Additional Paid in Capital		Accumulated Other Comprehensive Income		Retained Earnings		Total Equity			Shares (Note 1)	Amount		Additional Paid in Capital		Accumulated Other Comprehensive Income		Retained Earnings		Total Equity
Balance - December 31, 2021	Balance - December 31, 2021	648,794,041	$	648	$	302,866	$	—	$	220,784	$	524,298	Balance - December 31, 2021	648,794,041	$	648	$	302,866	$	—	$	220,784	$	524,298
Net income	Net income	—	—		—		—		61,961		61,961		Net income	—	—		—		—		61,961		61,961
Conversion of cash settled units to stock appreciation rights	Conversion of cash settled units to stock appreciation rights	—	—		1,632		—		—		1,632		Conversion of cash settled units to stock appreciation rights	—	—		1,632		—		—		1,632
Exercise of stock-settled stock appreciation rights	Exercise of stock-settled stock appreciation rights	117,180	—		348		—		—		348		Exercise of stock-settled stock appreciation rights	117,180	—		348		—		—		348
Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	(55,244)	—		(920)		—		—		(920)		Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights	(55,244)	—		(920)		—		—		(920)
Share-based compensation expense	Share-based compensation expense	—	—		1,696		—		—		1,696		Share-based compensation expense	—	—		1,696		—		—		1,696
Balance – March 31, 2022	Balance – March 31, 2022	648,855,977	$	648	$	305,622	$	—	$	282,745	$	589,015	Balance – March 31, 2022	648,855,977	648		305,622		—		282,745		589,015
Net income													Net income	—	—		—				87,715		87,715
Exercise of stock options													Exercise of stock options	231,846	1		739		—		—		740
Share-based compensation expense													Share-based compensation expense	—	—		1,727				—		1,727
Balance – June 30, 2022													Balance – June 30, 2022	649,087,823	649		308,088		—		370,460		679,197

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

Table of Contents

OLAPLEX HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(Unaudited)


		Three Months Ended March 31,					Six Months Ended June 30,
		2023		2022			2023		2022
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net income	Net income	$	20,964	$	61,961	Net income	$	27,120	$	149,676
Adjustments to reconcile net income to net cash from operations provided by operating activities:	Adjustments to reconcile net income to net cash from operations provided by operating activities:					Adjustments to reconcile net income to net cash from operations provided by operating activities:
Amortization of patent formulations	Amortization of patent formulations	1,742		1,769		Amortization of patent formulations	3,706		3,949
Amortization of other intangibles	Amortization of other intangibles	10,323		10,266		Amortization of other intangibles	20,647		20,561
Inventory write-off and disposal	Inventory write-off and disposal	2,610		4,324		Inventory write-off and disposal	6,167		4,324

Depreciation of fixed assets	Depreciation of fixed assets	116		75		Depreciation of fixed assets	230		152

Amortization of debt issuance costs	Amortization of debt issuance costs	453		146		Amortization of debt issuance costs	906		636
Deferred taxes	Deferred taxes	847		(1,712)		Deferred taxes	1,240		(3,537)
Share-based compensation expense	Share-based compensation expense	2,018		1,696		Share-based compensation expense	4,652		3,423
Loss on extinguishment of debt	Loss on extinguishment of debt	—		18,803		Loss on extinguishment of debt	—		18,803
Other operating	Other operating	265		—		Other operating	530		—
Changes in operating assets and liabilities, net of effects of acquisition (as applicable):	Changes in operating assets and liabilities, net of effects of acquisition (as applicable):					Changes in operating assets and liabilities, net of effects of acquisition (as applicable):
Accounts receivable, net	Accounts receivable, net	704		(28,135)		Accounts receivable, net	(4,078)		(40,566)
Inventory	Inventory	10,407		(22,899)		Inventory	10,657		(45,657)
Other current assets	Other current assets	(7,108)		1,425		Other current assets	(4,627)		3,856
Accounts payable	Accounts payable	(340)		9,838		Accounts payable	3,918		1,532
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	5,116		14,412		Accrued expenses and other current liabilities	4,047		10,901
Other assets and liabilities	Other assets and liabilities	(28)		—		Other assets and liabilities	(28)		—
Net cash provided by operating activities	Net cash provided by operating activities	48,089		71,969		Net cash provided by operating activities	75,087		128,053

Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchase of property and equipment	Purchase of property and equipment	(107)		(68)		Purchase of property and equipment	(128)		(75)
Purchase of intangible assets						Purchase of intangible assets	(500)		—
Purchase of software	Purchase of software	(524)		(421)		Purchase of software	(1,368)		(870)

Net cash used in investing activities	Net cash used in investing activities	(631)		(489)		Net cash used in investing activities	(1,996)		(945)

Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Proceeds from exercise of stock options	Proceeds from exercise of stock options	2,513		—		Proceeds from exercise of stock options	4,097		740
Payments for shares withheld and retired for taxes and exercise price for stock-settled share appreciation rights	Payments for shares withheld and retired for taxes and exercise price for stock-settled share appreciation rights	(64)		(572)		Payments for shares withheld and retired for taxes and exercise price for stock-settled share appreciation rights	(64)		(572)
Payment to pre-IPO stockholders pursuant to tax receivable agreement						Payment to pre-IPO stockholders pursuant to tax receivable agreement	(16,452)		—
Principal payments for 2022 Term Loan Facility, and principal payments and prepayment fees for 2020 Term Loan Facility	Principal payments for 2022 Term Loan Facility, and principal payments and prepayment fees for 2020 Term Loan Facility	(3,375)		(777,005)		Principal payments for 2022 Term Loan Facility, and principal payments and prepayment fees for 2020 Term Loan Facility	(5,062)		(778,692)

Proceeds from the issuance of 2022 Term Loan Facility	Proceeds from the issuance of 2022 Term Loan Facility	—		675,000		Proceeds from the issuance of 2022 Term Loan Facility	—		675,000
Payments of debt issuance costs	Payments of debt issuance costs	—		(11,944)		Payments of debt issuance costs	—		(11,944)
Net cash used in financing activities	Net cash used in financing activities	(926)		(114,521)		Net cash used in financing activities	(17,481)		(115,468)

Net increase (decrease) in cash and cash equivalents		46,532		(43,041)
Net increase in cash and cash equivalents						Net increase in cash and cash equivalents	55,610		11,640
Cash and cash equivalents - beginning of period	Cash and cash equivalents - beginning of period	322,808		186,388		Cash and cash equivalents - beginning of period	322,808		186,388
Cash and cash equivalents - end of period	Cash and cash equivalents - end of period	$	369,340	$	143,347	Cash and cash equivalents - end of period	$	378,418	$	198,028

Supplemental disclosure of cash flow information:	Supplemental disclosure of cash flow information:					Supplemental disclosure of cash flow information:
Cash paid for income taxes	Cash paid for income taxes	$	91	$	12	Cash paid for income taxes	$	9,511	$	35,176
Cash paid during the year for interest	Cash paid during the year for interest	$	13,853	$	10,597	Cash paid during the year for interest	$	29,344	$	13,491

Supplemental disclosure of noncash activities:	Supplemental disclosure of noncash activities:					Supplemental disclosure of noncash activities:
Public offering and strategic transition costs included in accounts payable and accrued expenses		$	—	$	145

Cash-settled units liability reclassification to additional paid in capital	Cash-settled units liability reclassification to additional paid in capital	$	—	$	1,632	Cash-settled units liability reclassification to additional paid in capital	$	—	$	1,632

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

OLAPLEX HOLDINGS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts, percentages and as otherwise indicated)

(Unaudited)

NOTE 1- NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Olaplex Holdings, Inc. (“Olaplex Holdings” and, together with its subsidiaries, the “Company”) is a Delaware corporation that was incorporated on June 8, 2021. Olaplex Holdings is organized as a holding company and operates indirectly through its wholly owned subsidiaries, Penelope and Olaplex, Inc., which conducts business under the name “Olaplex”. Olaplex is an innovative, science-enabled, technology-driven beauty company that is focused on delivering its patent-protected prestige hair care products to professional hair salons, retailers and everyday consumers. Olaplex develops, manufactures and distributes a line of hair care products developed to address three key uses: treatment, maintenance and protection.

Basis of Presentation

The accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim Condensed Consolidated Financial Statements furnished reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. The unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and accompanying footnotes included in the Company’s 2022 ~~Annual Report on~~ Form ~~10-K as filed on February 28, 2023.~~10-K.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates and Assumptions

Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Examples of estimates and assumptions include: for revenue recognition, determining the nature and timing of satisfaction of performance obligations, variable consideration, and other obligations such as product returns and refunds; loss contingencies; the fair value of share-based options and stock settled stock appreciation rights (“SARs”); the fair value of and/or potential impairment of goodwill and intangible assets for the Company’s reporting unit; the fair value of the Company’s interest rate cap; useful lives of the Company’s tangible and intangible assets; allowance for promotions; estimated income tax and tax receivable payments; the net realizable value of, and demand for the Company’s inventory. Actual results and outcomes may differ from management’s estimates and assumptions due to risks and uncertainties.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The authoritative guidance for fair value measurements established a framework for measuring fair value and established a three-level valuation hierarchy for disclosure of fair value measurements as follows:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company’s Level 1 assets consist of its marketable securities.

Level 2—Observable quoted prices for similar assets or liabilities in active markets and observable quoted prices for identical assets or liabilities in markets that are not active.

Level 3—Unobservable inputs that are not corroborated by market data.

Cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are reflected at carrying value, which approximates fair value due to the short-term maturity. The Company’s long-term debt is recorded at its carrying value in the Condensed Consolidated Balance Sheets, which may differ from fair value. The Company’s interest rate cap is recorded at its Level 3 fair value in the Condensed Consolidated Balance Sheets.

Accounting Policies

There have been no material changes in significant accounting policies as described in the Company’s Consolidated Financial Statements for the year ended December 31, 2022.

Constructive Retirement of Common Stock Repurchases

When the Company's common stock is retired or purchased for constructive retirement for net share settlement of stock options, any excess purchase price over par value is allocated between additional paid-in-capital, to the extent that previous net gains from sales or retirements are included therein, and the remainder to retained earnings.

Tax Receivable Agreement

As part of the IPO, the Company entered into the Tax Receivable Agreement under which the Company will be required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that the Company actually realizes on its taxable income following the IPO, as a result of the amortization of intangible assets and capitalized transaction costs that existed as of the date of the IPO. Under the Tax Receivable Agreement, generally the Company will retain the benefit of the remaining 15% of the applicable tax savings.

Reclassifications

Certain amounts presented have been reclassified within “Note 6 - Accrued Expenses and Other Current Liabilities” as of December 31, 2022 to conform with the current period presentation, including a prior year reclassification from Other accrued expenses and current liabilities to Accrued advertising. The reclassifications had no effect on the Company’s Total current liabilities.

NOTE 3 – NET SALES

The Company distributes products in the U.S. and internationally through professional distributors in the salon channel, directly to retailers for sale in their physical stores and e-commerce sites, and direct-to-consumer (“DTC”) through sales to third-party e-commerce customers and through its own Olaplex.com website. As such, the Company’s three business channels consist of professional, specialty retail and DTC as follows:


		For the Three Months Ended			For the Three Months Ended						For the Six Months Ended
			March 31, 2023			March 31, 2022			June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Net sales by Channel:	Net sales by Channel:							Net sales by Channel:
Professional	Professional		$	48,397		$	77,059	Professional	$	40,940	$	105,489	$	89,337	$	182,548
Specialty retail	Specialty retail		34,859			64,272		Specialty retail	29,767		64,229		64,626		128,501
DTC	DTC		30,531			44,865		DTC	38,534		41,185		69,065		86,050
Total net sales	Total net sales		$	113,787		$	186,196	Total net sales	$	109,241	$	210,903	$	223,028	$	397,099

Revenue by major geographic region is based upon the geographic location of customers who purchase the Company’s products. The majority of net sales are transacted in U.S. Dollars, the Company’s functional and reporting currency. During the three and six months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022, the Company’s net sales to consumers in the United States and International regions were as follows:


		For the Three Months Ended			For the Three Months Ended						For the Six Months Ended
			March 31, 2023			March 31, 2022			June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Net sales by Geography:	Net sales by Geography:							Net sales by Geography:
United States	United States		$	47,662		$	120,110	United States	$	50,099	$	121,320	$	97,761	$	241,430
International	International		66,125			66,086		International	59,142		89,583		125,267		155,669
Total net sales	Total net sales		$	113,787		$	186,196	Total net sales	$	109,241	$	210,903	$	223,028	$	397,099

United Kingdom (“U.K.”) net sales for the three and six months ended ~~March 31,~~June 30, 2023 were 9% of total net sales, and ~~March 31,~~for the three and six months ended June 30, 2022 were 9%8% of total net sales. No international country exceeded 10% of total net sales for the three and six months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022.

NOTE 4 - INVENTORY

Inventory as of ~~March 31,~~June 30, 2023 and December 31, 2022 consisted of the following:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Raw materials and packaging components	Raw materials and packaging components	$	40,224	$	36,194	Raw materials and packaging components	$	38,627	$	36,194
Finished goods	Finished goods	91,790		108,231		Finished goods	89,882		108,231
Inventory	Inventory	$	132,014	$	144,425	Inventory	$	128,509	$	144,425

During the three and six months ended June 30, 2023, the Company recorded write-offs of $3.6 million and $6.2 million of inventory due to product obsolescence, respectively. The Company did not record write-offs for product obsolescence during the same periods ended June 30, 2022.

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS

Goodwill and intangible assets are comprised of the following:


		March 31, 2023								June 30, 2023
		Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount			Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Brand name	Brand name	25 years	$	952,000	$	(122,914)	$	829,086	Brand name	25 years	$	952,000	$	(132,438)	$	819,562
Product formulations	Product formulations	15 years	136,000		(29,265)		106,735		Product formulations	15 years	136,500		(31,532)		104,968
Customer relationships	Customer relationships	20 years	53,000		(8,554)		44,446		Customer relationships	20 years	53,000		(9,216)		43,784
Software	Software	3 years	3,446		(751)		2,695		Software	3 years	4,290		(889)		3,401
Total finite-lived intangibles	Total finite-lived intangibles		1,144,446		(161,484)		982,962		Total finite-lived intangibles		1,145,790		(174,075)		971,715
Goodwill	Goodwill	Indefinite	168,300		—		168,300		Goodwill	Indefinite	168,300		—		168,300
Total goodwill and other intangibles	Total goodwill and other intangibles		$	1,312,746	$	(161,484)	$	1,151,262	Total goodwill and other intangibles		$	1,314,090	$	(174,075)	$	1,140,015


	December 31, 2022
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Brand name	25 years	$	952,000	$	(113,394)	$	838,606
Product formulations	15 years	136,000		(26,998)		109,002
Customer relationships	20 years	53,000		(7,892)		45,108
Software	3 years	2,922		(610)		2,312
Total finite-lived intangibles		1,143,922		(148,894)		995,028
Goodwill	Indefinite	168,300		—		168,300
Total goodwill and other intangibles		$	1,312,222	$	(148,894)	$	1,163,328

The amortization of the Company’s brand name, customer relationships and software is recorded to Amortization of other intangible assets in the Condensed Consolidated Statements of Operations and Comprehensive Income. A portion of Amortization of patented formulations is capitalized to Inventory in the Condensed Consolidated Balance Sheets, and the remainder is recorded to Amortization of patented formulations in the Condensed Consolidated Statements of Operations and Comprehensive Income. Amortization of the Company’s definite-lived intangible assets for the three and six months ended ~~March 31,~~June 30, 2023 and 2022 iswas as follows:


		For the Three Months Ended			For the Three Months Ended						For the Six Months Ended
			March 31, 2023			March 31, 2022			June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Amortization of patented formulations	Amortization of patented formulations		$	1,742		$	1,769	Amortization of patented formulations	$	1,964	$	2,180	$	3,706	$	3,948

Amortization expense, brand name and customer relationships	Amortization expense, brand name and customer relationships		10,182			10,183		Amortization expense, brand name and customer relationships	10,186		10,182		20,368		20,365
Amortization expense, software	Amortization expense, software		141			83		Amortization expense, software	138		113		279		196
Amortization of other intangible assets	Amortization of other intangible assets		10,323			10,266		Amortization of other intangible assets	10,324		10,295		20,647		20,561

Amortization of patented formulations capitalized to inventory	Amortization of patented formulations capitalized to inventory		$	525		$	497	Amortization of patented formulations capitalized to inventory	$	303	$	86	$	828	$	585

NOTE 6 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses as of ~~March 31,~~June 30, 2023 and December 31, 2022 consisted of the following:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Accrued advertising						Accrued advertising	7,784		1,356
Accrued legal settlement						Accrued legal settlement	5,250		—
Accrued professional fees	Accrued professional fees	$	3,911	$	3,187	Accrued professional fees	3,750		3,187
Accrued legal settlement		3,900		—
Accrued freight						Accrued freight	2,251		3,283
Deferred revenue						Deferred revenue	2,077		2,015
Payroll liabilities	Payroll liabilities	2,792		4,092		Payroll liabilities	1,749		4,092
Deferred revenue		2,230		2,015
Accrued freight		2,213		3,283
Accrued advertising		2,092		1,356
Other accrued expenses and current liabilities						Other accrued expenses and current liabilities	1,708		2,360
Accrued interest	Accrued interest	703		814		Accrued interest	80		814
Other accrued expenses and current liabilities		2,078		2,360
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	$	19,919	$	17,107	Accrued expenses and other current liabilities	$	24,649	$	17,107

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, the Company accrued approximately $3.9 million related to a pending settlement of a copyright matter. The Company expects to recover this settlement amount under its general liability insurance policy. An offset to the liability related to the insurance receivable is recorded in “Other current assets” on the Company’s Condensed Consolidated Balance Sheet ~~for the three months ended March 31,~~as of June 30, 2023.

NOTE 7 - LONG-TERM DEBT

The Company’s Long-Term Debt as of ~~March 31,~~June 30, 2023 and December 31, 2022 consisted of the following:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Long-term debt	Long-term debt					Long-term debt
Credit Agreement, dated as of February 23, 2022 (the “2022 Credit Agreement”)	Credit Agreement, dated as of February 23, 2022 (the “2022 Credit Agreement”)					Credit Agreement, dated as of February 23, 2022 (the “2022 Credit Agreement”)
$675 Million 7-Year Senior Secured Term Loan Facility (the “2022 Term Loan Facility”)	$675 Million 7-Year Senior Secured Term Loan Facility (the “2022 Term Loan Facility”)	$	668,250	$	671,625	$675 Million 7-Year Senior Secured Term Loan Facility (the “2022 Term Loan Facility”)	$	666,563	$	671,625
$150 Million 5-Year Senior Secured Revolving Credit Facility (the “2022 Revolver”)(1)	$150 Million 5-Year Senior Secured Revolving Credit Facility (the “2022 Revolver”)(1)	—		—		$150 Million 5-Year Senior Secured Revolving Credit Facility (the “2022 Revolver”)(1)	—		—

Debt issuance costs	Debt issuance costs	(8,494)		(8,854)		Debt issuance costs	(8,135)		(8,854)
Total term loan debt	Total term loan debt	659,756		662,771		Total term loan debt	658,428		662,771
Less: Current portion	Less: Current portion	(6,750)		(8,438)		Less: Current portion	(6,750)		(8,438)
Long-term debt, net of debt issuance costs and current portion	Long-term debt, net of debt issuance costs and current portion	$	653,006	$	654,333	Long-term debt, net of debt issuance costs and current portion	$	651,678	$	654,333

(1) As of ~~March 31,~~June 30, 2023 and December 31, 2022, the Company did not have outstanding amounts drawn on the 2022 Revolver, including letters of credit and swingline loan sub-facilities. As of ~~March 31,~~June 30, 2023, the Company had $150 million of available borrowing capacity under the 2022 Revolver.

The interest rate on outstanding debt under the 2022 Term Loan Facility was ~~8.4%~~8.70% per annum as of ~~March 31,~~June 30, 2023. The interest rates for all facilities under the 2022 Credit Agreement are calculated based upon the Company’s election among (a) adjusted term SOFR plus an additional interest rate spread, (b) with respect to a borrowing in Euros under the 2022 Revolver, a euro interbank offered rate plus an additional interest rate spread, or (c) an “Alternate Base Rate” (as defined in the 2022 Credit Agreement) plus an additional interest rate spread.

Interest expense, net, inclusive of debt amortization, for the three months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022 was ~~$10,543~~$10.2 million and ~~$11,460~~$8.7 million respectively, and for the six months ended June 30, 2023 and June 30, 2022 was $20.7 million and $20.2 million, respectively.

The fair value of the Company’s long-term debt is based on the market value of its long-term debt instrument. Based on the inputs used to value the long-term debt, the Company’s long-term debt is categorized within Level 2 in the fair value hierarchy. As of ~~March 31,~~June 30, 2023, the carrying amount of the Company’s long-term debt under the 2022 Credit Agreement was ~~$659.8~~$658.4 million, and the fair value of the Company’s long-term debt was ~~$593.1~~$626.6 million. As of December 31, 2022, the carrying amount of the Company’s long-term debt under the 2022 Credit Agreement was $662.8 million, and the fair value of the Company’s long-term debt was $624.6 million.

The 2022 Credit Agreement includes, among other things, customary negative and affirmative covenants (including reporting, financial and maintenance covenants) and events of default (including a change of control) for facilities of this type. In addition, the 2022 Credit Agreement includes a springing first lien leverage ratio financial covenant, which is applicable only to the lenders under the 2022 Revolver. The Company was in compliance with its financial covenants on ~~March 31,~~June 30, 2023 and December 31, 2022. The 2022 Term Loan Facility and the 2022 Revolver are secured by substantially all of the assets of Olaplex, Inc. and the other guarantors, subject to certain exceptions and thresholds.

Interest Rate Cap Transaction

The Company’s results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit Agreement, including the 2022 Term Loan Facility. The Company may, from time to time, utilize interest rate derivatives in an effort to add stability to interest expense and to manage its exposure to interest rate movements. On August 11, 2022, the Company entered into an interest rate cap transaction (the “interest rate cap”) in connection with the 2022 Term Loan Facility, with a notional amount of $400 million. Interest rate caps designated as cash flow hedges involve the receipt of variable amounts from a counterparty if interest rates rise above the strike rate applicable to the transaction, in exchange for an up-front premium paid by the Company. The Company has designated the interest rate cap as a cash-flow hedge for accounting purposes.

For derivatives designated, and that qualify, as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company’s accounting policy election.

The table below presents the fair value of the Company’s derivative financial instruments, which are classified within Other assets on the Company’s Condensed Consolidated Balance Sheets as of ~~March 31,~~June 30, 2023 and December 31, 2022.

March 31, 2023 December 31, 2022
Fair value, interest rate cap asset $ 4,051 $ 5,042



	June 30, 2023		December 31, 2022
Fair value, interest rate cap asset	$	5,493	$	5,042

During the three and six months ended ~~March 31,~~June 30, 2023, the Company’s interest rate cap generated an unrecognized pre-tax ~~loss~~gain of ~~$0.7~~$1.7 million and $1.0 million, respectively, recorded in Accumulated Other Comprehensive Income on the Company’s Condensed Consolidated Balance Sheets. ~~The~~During the same periods, the Company also recognized a ~~$0.6~~$0.9 million and $1.5 million reduction, respectively, in interest expense related to the Company’s receipt of funds as a result of an interest rate cap settlement with the Company’s counterparty, partially offset by $0.3 million and $0.5 million, respectively, related to amortization of the interest rate cap premium paid by the Company in connection with the interest rate cap. The Company did not have an interest rate cap agreement in place during the three and six months ended ~~March 31,~~June 30, 2022.

The Company performed an initial effectiveness assessment on the interest rate cap and determined it to be an effective hedge of the cash flows related to the interest rate payments on the 2022 Term Loan Facility. The hedge is evaluated qualitatively on a quarterly basis for effectiveness. Changes in fair value are recorded in Accumulated Other Comprehensive Income and periodic settlements of the interest rate cap will be recorded in interest expense along with the interest on amounts outstanding under the 2022 Term Loan Facility. Payment of the up-front premium of the interest rate cap is included within Other assets and liabilities within cash flows from operating activities on the Company’s Condensed Consolidated Statements of Cash Flows.

The Company does not hold or issue derivative financial instruments for trading purposes, nor does it hold or issue leveraged derivative instruments. By using derivative financial instruments to hedge exposures to interest rate fluctuations, the Company exposes itself to counterparty credit risk. The Company manages exposure to counterparty credit risk by entering into derivative financial instruments with highly rated institutions that can be expected to fully perform under the terms of the applicable contracts.

NOTE 8 - EQUITY

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, the Company issued 109,620 shares of its common stock upon vesting and settlement of net stock-settled SARs. The Company repurchased 83,501 of outstanding shares of its common stock for the net settlement of SARs for payment of taxes related to such SARs, which were accounted for as a share retirement.

Additionally, during the six months ended June 30, 2023, the Company issued ~~3,659,267~~4,413,328 shares of its common stock as a result of stock options exercised.

During the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company converted 886,950 cash-settled units into SARs, with a fair value liability of $1,632 reclassified from Accrued expenses and other current liabilities to Additional paid-in capital. The Company issued 117,180 shares of its common stock upon vesting and settlement of net stock-settled SARs. The Company repurchased 55,244 of outstanding shares of its common stock for the net settlement of SARs for payment of taxes related to such SARs, which were accounted for as a share retirement.

Additionally, during the six months ended June 30, 2022, the Company issued 231,846 shares of its common stock as a result of stock options exercised.

NOTE 9 - RELATED PARTY TRANSACTIONS

In July 2020, the Company entered into an agreement with CI&T, an information technology and software company, in which certain investment funds affiliated with Advent International Corporation, the holder of a majority of the Company’s common stock (collectively the “Advent Funds”), hold a greater than 10% equity interest. During the three and six months ended ~~March 31,~~June 30, 2023, the Company paid CI&T ~~$6.~~$6 and $12, respectively. During the three and six months ended ~~March 31,~~June 30, 2022, the Company paid CI&T ~~$5.~~$22 and $27, respectively. The Company engaged CI&T for services related to the development, maintenance and enhancement of the Olaplex professional application, as well as other digital marketing services, all of which were negotiated on an arm’s length basis and on market terms.

Tax Receivable Agreement

In connection with the Reorganization Transactions, the Company entered into the Tax Receivable Agreement with the Pre-IPO Stockholders. See further discussion in “Note 2 – Summary of Significant Accounting Policies – Tax Receivable Agreement”. During the three and six months ended June 30, 2023, the Company made a payment to the Pre-IPO Stockholders of $16.6 million as required pursuant to the terms of the Tax Receivable Agreement. During the three and six months ended June 30, 2022, the Company did not make a payment to the Pre-IPO Stockholders.

NOTE 10 - CONTINGENCIES

From time to time, the Company is subject to various legal actions arising in the ordinary course of business. The Company cannot predict with reasonable assurance the outcome of these legal actions brought against usthe Company as they are subject to uncertainties. Accordingly, any settlement or resolution in these legal actions may occur and affect the Company’s net income in such period as the settlement or resolution.

Pending Legal Proceedings:

On November 17, 2022, a putative securities class action was filed against the Company and certain of its current and former officers and directors in the United States District Court for the Central District of California, captioned Lilien v. Olaplex Holdings, Inc. et al., No. 2:22-cv-08395. A consolidated complaint was filed on April 28, 2023, which names as additional defendants the underwriters for the Company’s IPO and various stockholders that sold shares of common stock of the Company in the IPO. The action is brought on behalf of a putative class of purchasers of the Company’s common stock in or traceable to the Company’s IPO and asserts claims under Sections 11, 12, and 15 of the Securities Act of 1933. The action seeks certification of the putative class, compensatory damages, attorneys’ fees and costs, and any other relief that the court determines is appropriate. The ~~Company expects~~defendants moved to dismiss the consolidated complaint on July 19, 2023. The underwriter defendants ~~to notify~~have notified the Company of their intent to seek indemnification from the Company pursuant to the IPO underwriting agreement regarding the claims asserted in this action. The Company intends to vigorously defend the pending lawsuit.

On February 9, 2023, twenty-eight plaintiffs filed Albahae, et al. v. Olaplex Holdings, Inc., et al., No. 2:23-cv-00982, a complaint alleging personal and economic injury and asserting claims for breach of warranty, negligence/gross negligence, products liability, unjust enrichment, and violations of California False Advertising Law and Unfair Competition Law, against the Company and Cosway Company, Inc., the Company’s primary contract manufacturer, in the United States District Court for the Central District of California. On March 2, 2023, the plaintiffs amended the complaint to include seventy-three additional plaintiffs. The plaintiffs allege that certain ingredients used in some Company products have purportedly caused irritation or posed a hazard to consumers, and that the Company engaged in misrepresentation with respect to those products. The plaintiffs seek actual and consequential damages, punitive damages, restitution in the form of disgorgement of profits, attorneys’ fees and costs, and any other relief that the court determines is appropriate. ~~The Company intends to vigorously defend the pending lawsuit.~~ On April 17, 2023, the Company moved to dismiss and to sever the plaintiffs’ claims. On July 11, 2023, the Court granted the Company’s motion to sever and dismissed all but the first named plaintiff. The Court also dismissed the operative complaint with leave to re-file on the grounds that it now contained allegations that were not relevant to the claims of the one, remaining plaintiff. On July 24, 2023, the remaining plaintiff filed a notice, voluntarily dismissing her claims without prejudice.

Any potential loss associated with these pending legal proceedings is not probable or reasonably estimable at this time.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, the Company was not subject to any other currently pending legal matters or claims that could have a material adverse effect on its financial position, results of operations, or cash flows should such litigation be resolved unfavorably.

NOTE 11 – NET INCOME PER SHARE

The following is a reconciliation of the numerator and denominator in the basic and diluted net income per common share computations:


		Three Months Ended			Three Months Ended						Six Months Ended
			March 31, 2023			March 31, 2022			June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Numerator:	Numerator:							Numerator:
Net Income			$	20,964		$	61,961
Net income								Net income	$	6,156	$	87,715	$	27,120	$	149,676

Denominator:	Denominator:							Denominator:
Weighted average common shares outstanding – basic	Weighted average common shares outstanding – basic		651,730,993			648,813,998		Weighted average common shares outstanding – basic	654,345,056		648,973,952		653,045,245		648,894,417
Dilutive common equivalent shares from equity options	Dilutive common equivalent shares from equity options		31,754,189			44,207,099		Dilutive common equivalent shares from equity options	26,004,105		42,391,120		29,062,487		44,090,671
Weighted average common shares outstanding – diluted	Weighted average common shares outstanding – diluted		683,485,182			693,021,097		Weighted average common shares outstanding – diluted	680,349,161		691,365,072		682,107,732		692,985,088

Net income per share:	Net income per share:							Net income per share:
Basic	Basic		$	0.03		$	0.10	Basic	$	0.01	$	0.14	$	0.04	$	0.23
Diluted	Diluted		$	0.03		$	0.09	Diluted	$	0.01	$	0.13	$	0.04	$	0.22

1516

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report and with our audited Consolidated Financial Statements included in the 2022 Form 10-K.

Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from management’s expectations as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section “Special Note Regarding Forward-Looking Statements” in this Quarterly Report and in “Item 1A. – Risk Factors” in the 2022 Form 10-K.

Company Overview

OLAPLEX is an innovative, science-enabled, technology-driven beauty company. Since our inception in 2014, we have focused on delivering effective, patent-protected and proven product performance in the prestige hair care category. Our mission is to blaze new paths to well-being that ignite confidence from the inside out.

OLAPLEX disrupted and revolutionized the prestige hair care category by creating the bond-building space in 2014. We have grown from an initial assortment of three products sold exclusively through the professional channel to a broader suite of products offered through the professional, specialty retail and DTC channels that have been developed to address three key uses: treatment, maintenance and protection. Our patent-protected bond-building technology relinks disulfide bonds in human hair that are destroyed via chemical, thermal, mechanical, environmental and aging processes. Our current product portfolio comprises ~~sixteen~~seventeen unique, complementary products specifically developed to provide a holistic regimen for hair health.

The strength of our business model and ability to scale have created a compelling financial profile historically characterized by revenue growth and very strong profitability. We have developed a mutually reinforcing, synergistic, omnichannel model that leverages the strength of each of our channels and our strong digital capabilities that we apply across our sales platforms. Our professional channel serves as the foundation for our brand. Through this channel, professional hairstylists introduce consumers to our products and, we believe, influence consumer purchasing decisions. Our specialty retail channel works to increase awareness of, and education for, our products and expand consumer penetration. Our DTC channel, comprised of Olaplex.com and sales through third-party e-commerce platforms, also provides us with the opportunity to engage directly with our consumers to provide powerful feedback that drives decisions we make around new product development.

Four Strategic Pillars

We are focused on executing against four key strategic pillars that we believe will support our long-term growth. These include igniting our global brand, disrupting with innovation, amplifying channel coverage and charting new geographies. These key strategic pillars are supported by our efforts to build capabilities and infrastructure that we believe will enable our aspirations.

Igniting our Global Brand

We believe we have built one of the most powerful brands in the prestige hair care category. We plan to continue growing awareness of our global brand, in an effort to deepen connections with existing customers as well as reach new audiences. We will also continue to invest in enhancing our brand equity. Our marketing model remains focused on implementing high return on investment, performance marketing activities aimed at fueling growth. Key levers of our marketing include creative campaigns, organic social media activations, strategic paid media, education and training regarding our brand, community engagement with our professional hairstylists, influencer partnerships, and retailer activations such as sampling and in-store events.

Disrupting with Innovation

We believe we have a strong pipeline of disruptive innovation that leverages our science-based technology and patented Bis-amino ingredient. We plan to launch two-to-four products annually over the next five years. To support this pipeline, we intend to continue to invest in research and development to strengthen our internal innovation capabilities. ~~In March 2023, we entered our first hair care adjacency with the launch of LASHBOND, an eyelash-enhancing serum.~~ We remain excited about the opportunity to enter additional hair care adjacent categories and also other categories where our patents can serve as a foundation for entry that we believe is supported by consumer trust in our brand.

1617

Amplifying Channel Coverage

In our professional channel, we have undertaken efforts to support strong relationships with the hairstylist community and maintain brand awareness by increasing our field support efforts, deepening partnerships with distributors and customers, and refreshing educational content. We ~~also intend to pursue~~are pursuing opportunities to further penetrate premium and prestige salons. In specialty retail, we are enhancing visual merchandising in stores and deploying targeted communications intended to enable new customer acquisition. For our DTC business, we are evolving the digital experiences on Olaplex.com and third party e-commerce websites. On Olaplex.com, we expect to continue to invest in site enhancements and more advanced personalization efforts.

Charting New Geographies

We believe there is substantial opportunity to grow globally. Our priority international regions are currently key markets in Europe and Asia. Across Europe and other regions, we aim to implement our business model by first establishing a strong professional channel and then complementing that channel through entry into specialty retail and DTC. In Asia, we intend to partner with distributors in the region that will support the omni-channel distribution and sales for our brand.

Supporting our Four Strategic Pillars

To enable these four key growth pillars, we intend to continue to build our capabilities and infrastructure. These efforts extend across our organization, including focusing on cultivating top talent and building a strong corporate culture, evolving our operational capabilities as we scale, and ensuring that we have financial structure, technology and data to support our growth.

Business Environment & Trends

We continue to monitor the effects of the global macro-economic environment, including lower customer demand, the risk of recession, ~~increasing~~ inflationary pressures, competitive product discounting, currency volatility, rising interest rates, social and political issues, geopolitical tensions and regulatory matters. We also are mindful of inflationary pressures on our consumers, and are monitoring the impact that ~~increasing~~these inflationary pressures may have on consumer spending and preferences and inventory rebalancing at our customers in an increasingly competitive industry.

Competition in the beauty industry is based on a variety of factors, including innovation, product efficacy, accessible pricing, brand recognition and loyalty, service to the consumer, promotional activities, advertising, special events, new product introductions, e-commerce initiatives and other activities. ~~In recent years, we~~We have seen increased competitive activity including discounting in the prestige hair care category, which may continue in a heightened inflationary environment. We believe we have a well-recognized and strong reputation in our core markets and that the quality and performance of our products, our emphasis on innovation, and our engagement with our professional and consumer communities position us to compete effectively.

Overview of ~~first quarter~~Second Quarter 2023 ~~financial results~~Financial Results

•Net sales decreased ~~38.9%~~48.2% from ~~$186.2~~$210.9 million in the three months ended ~~March 31,~~June 30, 2022 to ~~$113.8~~$109.2 million in the three months ended ~~March 31,~~June 30, 2023. For the three months ended ~~March 31,~~June 30, 2023, net sales in our professional channel decreased ~~37.2%~~61.2%, our specialty retail channel decreased ~~45.8%,~~53.7% and our DTC channel decreased ~~31.9%~~6.4%, in each case as compared to the three months ended ~~March 31,~~June 30, 2022.

•Gross profit margin decreased from ~~75.8%~~74.2% in the three months ended ~~March 31,~~June 30, 2022 to 70.9% in the three months ended June 30, 2023, primarily as a result of a reserve for product obsolescence and higher input costs for raw materials and warehousing, partially offset by channel mix and increased net sales during the second quarter of 2022 in advance of the Company’s price increases which became effective as of July 1, 2022.

•Operating expenses for the three months ended June 30, 2023 increased by 61.3%, as compared to the three months ended June 30, 2022, primarily as a result of increased investments in marketing, professional fees, legal settlement costs, and a one-time former distributor payment, higher payroll due to workforce expansion, and higher employee benefit costs, partially offset by lower distribution and fulfillment costs incurred in the three months ended June 30, 2023.

•Operating income decreased from $120.0 million for the three months ended June 30, 2022 to $18.8 million for the three months ended June 30, 2023.

•Net income decreased from $87.7 million for the three months ended June 30, 2022 to $6.2 million for the three months ended June 30, 2023.

Overview of Year to Date 2023 Financial Results

•Net sales decreased 43.8% from $397.1 million in the six months ended June 30, 2022 to $223.0 million in the six months ended June 30, 2023. For the six months ended June 30, 2023, net sales in our professional channel decreased 51.1%, our specialty retail channel decreased 49.7%, and our DTC channel decreased 19.7%, in each case as compared to the six months ended June 30, 2022.

•Gross profit margin decreased from 75.0% in the six months ended June 30, 2022 to 71.0% in the ~~three~~six months ended ~~March 31,~~June 30, 2023, primarily as a result of higher input costs for raw materials and warehousing, aand increased reserve for product obsolescence, ~~and~~partially offset by product and channel mix ~~partially offset by inventory write-off~~ and ~~disposal costs recorded~~increased net sales during the ~~three months ended March 31,~~second quarter of 2022 in advance of the Company’s price increases which became effective as of July 1, 2022.

•Operating expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased by ~~38.9%~~50.7%, as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022, primarily as a result of increased ~~sales~~investments in marketing, professional expenses, legal settlement costs and ~~marketing expense,~~a one-time former distributor payment, higher payroll due to workforce expansion, and higher ~~professional fees and other~~employee benefit costs, partially offset by decreased distribution and fulfillment expenses.

•Operating income decreased from ~~$108.6~~$228.6 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 to ~~$35.6~~$54.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023.

•Net income decreased from ~~$62.0~~$149.7 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 to ~~$21.0~~$27.1 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023.

Results of operations

Comparison of the Three Months Ended ~~March 31,~~June 30, 2023 to the Three Months Ended ~~March 31,~~June 30, 2022

The following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data for each of the periods presented:


		Three Months Ended March 31,									Three Months Ended June 30,
		2023				2022					2023				2022
		(in thousands)		% of Net sales		(in thousands)		% of Net sales			(in thousands)		% of Net sales		(in thousands)		% of Net sales
Net sales	Net sales	$	113,787	100.0	%	$	186,196	100.0	%	Net sales	$	109,241	100.0	%	$	210,903	100.0	%
Cost of sales:	Cost of sales:									Cost of sales:
Cost of product (excluding amortization)	Cost of product (excluding amortization)	31,235		27.5		43,222		23.2		Cost of product (excluding amortization)	29,781		27.3		52,293		24.8
Amortization of patented formulations	Amortization of patented formulations	1,742		1.5		1,769		1.0		Amortization of patented formulations	1,964		1.8		2,180		1.0
Total cost of sales	Total cost of sales	32,977		29.0		44,991		24.2		Total cost of sales	31,745		29.1		54,473		25.8
Gross profit	Gross profit	80,810		71.0		141,205		75.8		Gross profit	77,496		70.9		156,430		74.2
Operating expenses:	Operating expenses:									Operating expenses:
Selling, general, and administrative	Selling, general, and administrative	34,924		30.7		22,314		12.0		Selling, general, and administrative	48,413		44.3		26,111		12.4
Amortization of other intangible assets	Amortization of other intangible assets	10,323		9.1		10,266		5.5		Amortization of other intangible assets	10,324		9.5		10,295		4.9

Total operating expenses	Total operating expenses	45,247		39.8		32,580		17.5		Total operating expenses	58,737		53.8		36,406		17.3
Operating income	Operating income	35,563		31.3		108,625		58.3		Operating income	18,759		17.2		120,024		56.9
Interest expense		(10,543)		(9.3)		(11,460)		(6.2)
Other income (expense), net
Loss on extinguishment of debt		—		—		(18,803)		(10.1)
Other income (expense), net		242		0.2		(377)		(0.2)
Total other income (expense), net		242		0.2		(19,180)		(10.3)
Interest expense, net										Interest expense, net	(10,206)		(9.3)		(8,694)		(4.1)

Other expense, net										Other expense, net	(600)		(0.5)		(1,224)		(0.6)
Income before provision for income taxes	Income before provision for income taxes	25,262		22.2		77,985		41.9		Income before provision for income taxes	7,953		7.3		110,106		52.2
Income tax provision	Income tax provision	4,298		3.8		16,024		8.6		Income tax provision	1,797		1.6		22,391		10.6
Net income	Net income	$	20,964	18.4	%	$	61,961	33.3	%	Net income	$	6,156	5.6		$	87,715	41.6

Net Sales

(in thousands) For the Three Months Ended March 31,
2023 2022 $ Change % Change
Net sales by Channel:
Professional $ 48,397 $ 77,059 $ (28,662) (37.2) %
Specialty retail 34,859 64,272 (29,413) (45.8) %
DTC 30,531 44,865 (14,334) (31.9) %
Total net sales $ 113,787 $ 186,196 $ (72,409) (38.9) %
We distribute products in the U.S. and internationally through professional distributors in the salon channel, directly to retailers for sale in their physical stores and e-commerce sites, and DTC through sales to third party e-commerce customers and through our Olaplex.com websites. As such, our three business channels consist of professional, specialty retail and

DTC as follows:


(in thousands)	For the Three Months Ended June 30,
	2023		2022		$ Change		% Change
Net sales by Channel:
Professional	$	40,940	$	105,489	$	(64,549)	(61.2)	%
Specialty retail	29,767		64,229		(34,462)		(53.7)	%
DTC	38,534		41,185		(2,651)		(6.4)	%
Total Net sales	$	109,241	$	210,903	$	(101,662)	(48.2)	%

Total net sales declined ~~38.9%~~48.2% in the three months ended ~~March 31,~~June 30, 2023 compared to the same period in 2022, ~~which the Company attributes~~ primarily attributed to a lower ~~baseline~~ level of demand ~~a negative year over year~~and inventory rebalancing, particularly within our Professional and Specialty Retail channels. Lapping our introduction of certain 1-Liter size offerings during the second quarter of 2022 contributed to $22.0 million of the net sales impact, and approximately $10.0 million of increased net sales during the second quarter of 2022 were in advance of the Company’s price increases which became effective as of July 1, 2022. These impacts were partially offset by our launches of Volumizing Blow Dry Mist, LASHBOND™ Serum, which is our first hair care adjacent product, and No. 4D Clean Volume Detox Dry Shampoo, as well as the impact of ~~approximately $21~~new customers within each channel and the overall mix shift to DTC. Net sales declined primarily in the United States, Canada and the United Kingdom, partially offset by increases in Southeast Asia.

Cost of Sales and Gross Profit


(in thousands)	For the Three Months Ended June 30,				$ Change		% Change
	2023		2022
Cost of sales	$	31,745	$	54,473	$	(22,728)	(41.7)	%
Gross profit	$	77,496	$	156,430	$	(78,934)	(50.5)	%

Our cost of sales decreased primarily due to declining product sales in the three months ended June 30, 2023. These decreases were partially offset by a $3.6 million inventory obsolescence reserve recorded during the three months ended June 30, 2023, and increases in cost of sales resulting from inflationary pressures and sales deleverage.

As a result of the activity described above regarding Net sales and Cost of sales, our gross profit margin decreased from 74.2% in the three months ended June 30, 2022 to 70.9% in the three months ended June 30, 2023.

Operating Expenses


(in thousands)	For the Three Months Ended June 30,
	2023		2022		$ Change		% Change
Selling, general, and administrative expenses	$	48,413	$	26,111	$	22,302	85.4	%
Amortization of other intangible assets	10,324		10,295		29		0.3	%

Total operating expenses	$	58,737	$	36,406	$	22,331	61.3	%

The increase in selling, general and administrative expenses was primarily driven by an increase of $14.1 million in investments in sales and marketing, $5.9 million related to a one-time former distributor payment, legal settlement costs, and professional expenses, $1.4 million in payroll expenses driven by workforce expansion, and $0.9 million of employee benefit costs, partially offset by a $0.8 million decrease in distribution and fulfillment costs related to the decrease in product sales volume during the three months ended June 30, 2023.

Interest Expense, Net


(in thousands)	For the Three Months Ended June 30,
	2023		2022		$ Change		% Change
Interest expense, net	$	(10,206)	$	(8,694)	$	(1,512)	17.4	%

Interest expense, net increased due to increased interest rates in response to the inflationary environment during the three months ended June 30, 2023. See “Liquidity and Capital Resources Requirements – Credit Facility” for additional information regarding our outstanding debt.

We also benefited during the three months ended June 30, 2023 from $4.5 million of interest income from highly liquid investments with a maturity of three months or less.

Other Expense, Net


(in thousands)	For the Three Months Ended June 30,
	2023		2022		$ Change		% Change


Other expense, net	$	(600)	$	(1,224)	$	624	(51.0)	%

Other expense, net decreased primarily due to lower foreign currency transaction losses driven by the performance of the U.S. dollar.

Income Tax Provision


(in thousands)	For the Three Months Ended June 30,
	2023		2022		$ Change		% Change
Income tax provision	$	1,797	$	22,391	$	(20,594)	(92.0)	%

Our effective tax rate was 22.6% for the three months ended June 30, 2023, as compared to 20.3% for the three months ended June 30, 2022. Our effective tax rate for the three months ended June 30, 2023 is higher than the statutory tax rate of 21% due to the effect of state income taxes, partially offset by the foreign derived intangible income deduction (“FDII”), which results in income from our sales to foreign customers being taxed at a lower effective tax rate. Our effective tax rate for the three months ended June 30, 2022 was lower than the statutory tax rate of 21% primarily due to the benefit associated with the FDII, partially offset by the net impact of state income taxes. The increase in the effective tax rate from the comparative prior three month period is primarily due to an additional state income tax expense recorded in the three months ended June 30, 2023, which had a disproportionate impact on the effective tax rate due to the lower profitability for the period.

Comparison of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022

The following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data for each of the periods presented:


	Six Months Ended June 30,
	2023				2022
	(in thousands)		% of Net sales		(in thousands)		% of Net sales
Net sales	$	223,028	100.0	%	$	397,099	100.0	%
Cost of sales:
Cost of product (excluding amortization)	61,016		27.4		95,515		24.1
Amortization of patented formulations	3,706		1.7		3,949		1.0
Total cost of sales	64,722		29.0		99,464		25.0
Gross profit	158,306		71.0		297,635		75.0
Operating expenses:
Selling, general, and administrative	83,337		37.4		48,425		12.2
Amortization of other intangible assets	20,647		9.3		20,561		5.2

Total operating expenses	103,984		46.6		68,986		17.4
Operating income	54,322		24.4		228,649		57.6
Interest expense	(20,749)		(9.3)		(20,154)		(5.1)
Other income (expense), net
Loss on extinguishment of debt	—		—		(18,803)		(4.7)
Other income (expense), net	(358)		(0.2)		(1,601)		(0.4)
Total other income (expense), net	(358)		(0.2)		(20,404)		(5.1)
Income before provision for income taxes	33,215		14.9		188,091		47.4
Income tax provision	6,095		2.7		38,415		9.7
Net income	$	27,120	12.2		$	149,676	37.7

Net Sales

Net sales by channel for the six months ended June 30, 2023 and June 30, 2022 were as follows:


(in thousands)	For the Six Months Ended June 30,
	2023		2022		$ Change		% Change
Net sales by Channel:
Professional	$	89,337	$	182,548	$	(93,211)	(51.1)	%
Specialty retail	64,626		128,501		(63,875)		(49.7)	%
DTC	69,065		86,050		(16,985)		(19.7)	%
Total net sales	$	223,028	$	397,099	$	(174,071)	(43.8)	%

Total net sales declined 43.8% in the six months ended June 30, 2023 compared to the same period in 2022, primarily attributed to a lower level of demand and inventory rebalancing, atparticularly within the Professional and Specialty Retail channels. Lapping our introduction of certain ~~professional~~1-Liter size offerings during the second quarter of 2022 contributed to $22.0 million of the net sales impact, approximately $10.0 million of increased net sales during the second quarter of 2022 were in advance of the Company’s price increases which became effective as of July 1, 2022, and ~~specialty retail customers, and~~ lapping ~~$10 million of~~ inventory pipeline sold to a key specialty retailer in the first quarter of ~~2022. The lower baseline demand across each~~2022 contributed to approximately $10 million of ~~our three channels was~~net sales impact. These impacts were partially offset by our launches of LASHBOND™ Serum, which is our first hair care adjacent product, No. 4D Clean Volume Detox Dry Shampoo, and ~~prior year launches of 1-Liter sizes of our No. 4 Bond Maintenance Shampoo, No. 5 Bond Maintenance Conditioner, and No. 4C Bond Maintenance Clarifying Shampoo,~~Volumizing Blow Dry Mist, as well as the impact of new customers within each channel. Net sales declined primarily in the United States, ~~and~~ the United Kingdom, and Canada, partially offset by increases in ~~Italy.~~Southeast Asia and France.

1822

Cost of Sales and Gross Profit


(in thousands)	(in thousands)	For the Three Months Ended March 31,				$ Change					% Change		(in thousands)	For the Six Months Ended June 30,								$ Change			% Change
		2023		2022						2023					2022
Cost of sales	Cost of sales	$	32,977	$	44,991			$	(12,014)					(26.7)		%	Cost of sales	$	64,722		$	99,464		$	(34,742)		(34.9)	%
Gross profit	Gross profit	$	80,810	$	141,205	$	(60,395)				(42.8)	%	Gross profit	$	158,306				$	297,635		$	(139,329)		(46.8)	%

Our cost of sales decreased primarily due to declining product sales in the ~~three~~six months ended ~~March 31,~~June 30, 2023, and a $4.3 million expense recorded in the three months ended March 31, 2022 for inventory write-off and disposal costs related to unused stock of a product that the Company reformulated in June 2021 as a result of regulation changes in the European Union. These decreases were partially offset by increases in cost of sales resulting from inflationary pressures and a ~~$2.6~~$6.2 million reserve for product obsolescence recorded during the ~~three~~six months ended ~~March 31,~~June 30, 2023.

As a result of the activity described above regarding Net sales and Cost of sales, our gross profit margin decreased from ~~75.8%~~75.0% in the ~~three~~six months ended ~~March 31,~~June 30, 2022 to 71.0% in the ~~three~~six months ended ~~March 31,~~June 30, 2023.

Operating Expenses


(in thousands)	(in thousands)	For the Three Months Ended March 31,								(in thousands)	For the Six Months Ended June 30,
		2023		2022		$ Change		% Change			2023		2022		$ Change		% Change
Selling, general, and administrative expenses	Selling, general, and administrative expenses	$	34,924	$	22,314	$	12,610	56.5	%	Selling, general, and administrative expenses	$	83,337	$	48,425	$	34,912	72.1	%
Amortization of other intangible assets	Amortization of other intangible assets	10,323		10,266		57		0.6	%	Amortization of other intangible assets	20,647		20,561		86		0.4	%

Total operating expenses	Total operating expenses	$	45,247	$	32,580	$	12,667	38.9	%	Total operating expenses	$	103,984	$	68,986	$	34,998	50.7	%

Selling, general and administrative expenses increased primarily due to ~~increased~~an increase of $22.8 million in investments in sales and marketing, $6.8 million related to a one-time former distributor payment, professional expenses, and legal settlement costs, payroll expenses of ~~$8.6 million and higher payroll of $3.6~~$5.0 million driven by workforce expansion, ~~both~~and increased employee benefit costs of ~~which are expected to support our four strategic pillars. The Company also had increases of $1.9~~$2.2 million, ~~in professional fees and other benefit costs. These increases were~~ partially offset by a ~~$1.9~~$2.7 million decrease in distribution and fulfillment costs related to the decrease in product sales ~~volume.~~volume during the six months ended June 30, 2023.

Interest Expense, Net


(in thousands)	(in thousands)	For the Three Months Ended March 31,								(in thousands)	For the Six Months Ended June 30,
		2023		2022		$ Change		% Change			2023		2022		$ Change		% Change
Interest expense, net	Interest expense, net	$	(10,543)	$	(11,460)	$	917	(8.0)	%	Interest expense, net	$	(20,749)	$	(20,154)	$	(595)	3.0	%

Interest expense, net ~~decreased~~increased due to increased interest rates in response to the ~~Company refinancing its 2020 Credit Agreement with a new 2022 Credit Agreement in February 2022, which reduced~~inflationary environment during the ~~Company’s outstanding debt and lowered the interest rate in respect thereof in the three~~six months ended ~~March 31,~~June 30, 2023. See “Liquidity and Capital Resources Requirements – Credit Facility” for additional information on ~~the Company’s~~our outstanding debt. ~~The Company~~

We also benefited induring the ~~first quarter of~~six months ended June 30, 2023 from ~~$3.4~~$7.8 million of interest income from highly liquid investments with a maturity of three months or less.

Other ~~Income~~ (Expense), Net


(in thousands)	(in thousands)	For the Three Months Ended March 31,								(in thousands)	For the Six Months Ended June 30,
		2023		2022		$ Change		% Change			2023		2022		$ Change		% Change
Loss on extinguishment of debt	Loss on extinguishment of debt	$	—	$	(18,803)	$	18,803	—	%	Loss on extinguishment of debt	$	—	$	(18,803)	$	18,803	—	%
Other income (expense), net		242		$	(377)	$	619	(164.2)	%
Other expense, net										Other expense, net	(358)		$	(1,601)	$	1,243	(77.6)	%
Total other expense, net	Total other expense, net	$	242	$	(19,180)	$	19,422	(101.3)	%	Total other expense, net	$	(358)	$	(20,404)	$	20,046	(98.2)	%

As a result of the ~~debt~~ refinancing of the 2020 Credit Agreement that occurred during the ~~three~~six months ended ~~March 31,~~June 30, 2022, ~~as described above, the Company~~we recorded an $18.8 million loss on extinguishment of debt in that period. Other ~~Income (expense),~~expense, net ~~increased~~decreased in the ~~three~~six months ended ~~March 31,~~June 30, 2023 primarily due to ~~an increase~~a decrease in foreign currency transaction ~~gains~~losses driven by the performance of the U.S. dollar.

1923

Income Tax Provision


(in thousands)	(in thousands)	For the Three Months Ended March 31,								(in thousands)	For the Six Months Ended June 30,
		2023		2022		$ Change		% Change			2023		2022		$ Change		% Change
Income tax provision	Income tax provision	$	4,298	$	16,024	$	(11,726)	(73.2)	%	Income tax provision	$	6,095	$	38,415	$	(32,320)	(84.1)	%

Our effective tax rate was ~~17.0%~~18.4% for the ~~three~~six months ended ~~March 31,~~June 30, 2023, as compared to ~~20.5%~~20.4% for the ~~three~~six months ended ~~March 31,~~June 30, 2022. The decrease in the effective tax rate for the ~~three~~six months ended ~~March 31,~~June 30, 2023 is primarily due to a discrete tax ~~benefit~~benefits from stock option exercises and a one-time former distributor payment during that period. Additionally, ~~the Company’s~~our effective tax ~~rate in~~rates for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 ~~was~~are lower than the statutory tax rate of 21% primarily due to the benefit associated with the ~~foreign derived intangible income deduction (“FDII”), which results in income from the Company’s sales to foreign customers being taxed at a lower effective tax rate,~~FDII, partially offset by the net impact of state income taxes.

Tax Receivable Agreement

The ~~tax~~Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that the Company and its subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax Receivable Agreement. Updates to the blended state tax rate and allocation of U.S. versus foreign sourced income may impact the established liability and changes would be recorded to other income (expense) in the period we made the determination. ~~The Company expects~~We expect that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax Assets could aggregate to ~~$222.1~~$205.6 million over the 13-year remaining period under the Tax Receivable Agreement. Payments under the Tax Receivable Agreement, which began in the year ended December 31, 2022, are not conditioned upon the parties’ continued ownership of equity in the Company. During the three and six months ended June 30, 2023, the Company made a payment to the Pre-IPO Stockholders of $16.6 million as required pursuant to the terms of the Tax Receivable Agreement. During the three and six months ended June 30, 2022, the Company did not make a payment to the Pre-IPO Stockholders. The remaining Tax Receivable Agreement payment obligation as of ~~March 31,~~June 30, 2023 is ~~$222.1~~$205.6 million, of which ~~$205.7~~$189.4 million was recorded in long term liabilities and ~~$16.4~~$16.2 million was recorded in current liabilities.

Financial Condition, Liquidity and Capital Resources

Overview

Our primary recurring source of cash is the collection of proceeds from the sale of our products to our customers, including cash periodically collected in advance of delivery or performance.

Our primary use of cash is for working capital and payment of our operating costs, which consist primarily of employee-related expenses as well as general operating expenses for marketing, fulfillment costs of customer orders, overhead costs, innovation, capital expenditures and debt servicing. We also utilize cash for strategic investments. Fluctuations in working capital are primarily caused by customer demand of our product, timing of when a retailer rearranges or restocks our products, timing of inventory purchases, and timing of our payables and expenses. Capital expenditures typically vary and are currently limited, and future capital expenditure requirements depend on strategic initiatives selected for the fiscal year, including investments in infrastructure, expansion into new national and international distributors and expansion of our customer base.

A considerable portion of our operating income is ~~earned~~related to sales to customers outside of the U.S.; however, the majority of our bank deposits are held within the U.S.

As of ~~March 31,~~June 30, 2023, we had ~~$369.3~~$378.4 million of cash and cash equivalents. In addition, as of ~~March 31,~~June 30, 2023, we had borrowing capacity of $150.0 million under the 2022 Revolver, plus ~~$136.0~~$131.0 million of working capital excluding cash and cash equivalents for a combined liquidity position of $~~655.3~~659.4 million.

2024

Cash Flows

The following table summarizes our cash flows for the periods presented:

For the Three Months Ended March 31,
(in thousands) 2023 2022
Net cash provided by (used in):
Operating activities $ 48,089 $ 71,969
Investing activities (631) (489)
Financing activities (926) (114,521)
Net increase (decrease) in cash and cash equivalents: $ 46,532 $ (43,041)


	For the Six Months Ended June 30,
(in thousands)	2023		2022
Net cash provided by (used in):
Operating activities	$	75,087	$	128,053
Investing activities	(1,996)		(945)
Financing activities	(17,481)		(115,468)
Net increase in cash and cash equivalents:	$	55,610	$	11,640

Operating Activities

The decrease in net cash provided by operating activities during the ~~three~~six months ended ~~March 31,~~June 30, 2023 compared to the same period in 2022 was primarily a result of a decrease in net income of ~~$41.0~~$122.6 million, changes in working capital and adjusting items to Operating Cash Flows to reconcile to Net income from operations, and increases in inventory write-offs and disposal adjustments of $1.8 million, partially offset by the loss on extinguishment of debt of $18.8 million related to the refinancing of the 2020 Credit Agreement ~~as well as inventory write-offs and disposal adjustments of $4.3 million, in each case~~ recorded in the ~~three~~six months ended ~~March 31,~~June 30, 2022, and other changes in working capital between the comparative periods.

Investing Activities

~~The Company’s~~Our investing activities included purchases of software, property and equipment during the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022.

Financing Activities

~~The Company’s~~Our financing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2023 primarily consisted of cash outflows for payments on our long-term debt and debt issuance costs, payments to our pre-IPO stockholders pursuant to our Tax Receivable Agreement, and payments for shares withheld and retired for taxes and exercise price for SARs, partially offset by cash received by the Company from stock option exercises. For the ~~three~~six months ended ~~March 31,~~June 30, 2022, ~~the Company’s~~our financing activities primarily consisted of cash outflows for payments on our long-term debt and debt issuance costs, and payments for shares withheld and retired for taxes and exercise price for SARs, offset by proceeds from the issuance of the 2022 Credit ~~Agreement~~Agreement.

Liquidity and Capital Resources Requirements

Based on past performance and current expectations, we believe that our cash, cash equivalents and cash generated from operations will be sufficient to meet anticipated operating costs, required payments of principal and interest, working capital needs, ordinary course capital expenditures, and other commitments for at least the next 12 months.

If necessary, we may borrow funds under our 2022 Revolver to finance our liquidity requirements, subject to customary borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all. Our ability to meet our operating, investing and financing needs depends, to a significant extent, on our future financial performance, which will be subject in part to general economic, competitive, financial, regulatory and other factors that are beyond our control, including those described elsewhere in “Risk Factors” in our 2022 Form 10-K. In addition to these general economic and industry factors, the principal factors in determining whether our cash flows will be sufficient to meet our liquidity requirements will be our ability to continue providing innovative products to our customers and consumers and manage production and our supply chain.

2022 Credit Facility

As of ~~March 31,~~June 30, 2023, ~~the Company~~we had outstanding indebtedness under the 2022 Credit Agreement of ~~$668.3~~$666.6 million, of which $6.8 million was classified as current. As of ~~March 31,~~June 30, 2023, ~~the Company~~we had $150.0 million of available borrowing capacity under the 2022 Revolver.

The interest rate on outstanding amounts under the 2022 Term Loan Facility was ~~8.4%~~8.7% per annum as of ~~March 31,~~June 30, 2023. We have not drawn on the 2022 Revolver as of ~~March 31,~~June 30, 2023. The 2022 Term Loan Facility is repayable in mandatory quarterly installments equal to $1.7 million, with the balance payable at maturity.

2125

The 2022 Credit Agreement includes, among other things, customary negative and affirmative covenants (including reporting, financial, and maintenance covenants) and events of default (including a change of control) for facilities of this type. In addition, the 2022 Credit Agreement includes a springing first lien leverage ratio financial covenant, which is applicable only to the lenders under the 2022 Revolver. ~~The Company was~~We were in compliance with ~~its~~our financial covenants on ~~March 31,~~June 30, 2023 and December 31, 2022. The 2022 Term Loan Facility and the 2022 Revolver are secured by substantially all of the assets of Olaplex, Inc. and the other guarantors, subject to certain exceptions and thresholds.

On August 11, 2022, ~~the Company~~we entered into an interest rate cap transaction in connection with the 2022 Term Loan Facility, with a notional amount of $400.0 million, in order to limit its exposure to potential increases in future interest rates related to the 2022 Term Loan Facility. ~~The Company has~~We have designated the interest rate cap as a cash-flow hedge for accounting purposes.

See “Note 7. Long-Term-Debt” in the Notes to the Condensed Consolidated Financial Statements included in Item 1. Financial Statements of this Quarterly Report for additional information on ~~the Company’s~~our indebtedness and interest rate cap.

Tax Receivable Agreement Obligations

As part of the IPO, we entered into the Tax Receivable Agreement under which we will be required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that we actually realize on our taxable income following the IPO, as a result of the amortization of intangible assets and capitalized transaction costs that existed as of the transaction date. Under the Tax Receivable Agreement, generally we will retain the benefit of the remaining 15% of the applicable tax savings.

Contractual Obligations and Commitments

There were no material changes ~~outside the ordinary course of business~~ to our contractual obligations since the filing of our 2022 Form 10-K.

Critical Accounting Policies and Estimates

Our unaudited interim Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires us to make estimates and assumptions that affect reported amounts. The estimates and assumptions are based on historical experience and on other factors that we believe to be reasonable. Actual results may differ from those estimates. We review these estimates on a periodic basis to ensure reasonableness. Although actual amounts may differ from such estimated amounts, we believe such differences are not likely to be material. For additional detail regarding our critical accounting policies including revenue recognition, inventory, and the Tax Receivable Agreement, see our discussion for the year ended December 31, 2022 in the 2022 Form 10-K. There have been no material changes to these policies in the ~~three~~six months ended ~~March 31,~~June 30, 2023.

2226

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to certain market risks arising from transactions in the normal course of our business. This includes risk associated with interest rates, inflation and foreign exchange.

Interest Rate Risk

Our results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit Agreement. Our borrowings bear interest at a variable rate; therefore, we are exposed to market risks relating to changes in interest rates. When the reference rates under our 2022 Term Loan Facility increase, the interest payments we must make thereon also increase, which can impact our future earnings and cash flows. As of ~~March 31,~~June 30, 2023, we had ~~$668.3~~$666.6 million of outstanding variable rate loans under the 2022 Term Loan Facility. Based on our ~~March 31,~~June 30, 2023 variable rate loan balances, an increase or decrease of 1% in the effective interest rate would cause an increase or decrease in interest cost of approximately $6.7 million over the next 12 months.

Interest Rate Cap

On August 11, 2022, ~~the Company~~we entered into an interest rate cap transaction (the “interest rate cap”) in connection with the 2022 Term Loan Facility, as more fully described in “Note 7 - Long Term Debt” in the Notes to the Condensed Consolidated Financial Statements included in Item 1. Financial Statements of this Quarterly Report. ~~The Company uses~~We use the interest rate cap to add stability to interest expense and to manage ~~its~~our exposure to interest rate movements. The fair value of the interest rate cap is measured at the end of each reporting period using observable inputs other than quoted prices. The fair value of the interest rate cap recorded in other assets at ~~March 31,~~June 30, 2023 was ~~$4.1~~$5.5 million. A hypothetical 50 basis point increase in interest rates would result in an increase to the fair value of the interest rate cap of approximately ~~$1.5~~$1.4 million. A hypothetical 50 basis point decrease in interest rates would result in a decrease to the fair value of the interest rate cap of approximately ~~$1.2~~$1.3 million.

Inflation

Inflationary factors such as increases in the cost to produce our products and overhead costs have adversely affected, and may continue to adversely affect, our operating results. During the three and six months ended ~~March 31,~~June 30, 2023, ~~and fiscal year 2022,~~ our gross profit margin was negatively impacted by increased input costs for warehousing, transportation and raw materials. Sustained increases in warehousing costs, transportation costs, wages and raw material costs, or other inflationary pressures in the future, may have an adverse effect on our ability to maintain current levels of gross profit margin if the selling prices of our products do not increase with these increased costs, or if we cannot identify other cost efficiencies.

Foreign Exchange Risk

Our reporting currency, including our U.K. foreign subsidiary, Olaplex UK Limited, is the U.S. dollar. Gains or losses due to transactions in foreign currencies are reflected in the Consolidated Statements of Operations and Comprehensive Income under the line-item Other (expense) income, net. We have not engaged in the hedging of foreign currency transactions to date, although we may choose to do so in the future. We do not believe that an immediate 10% increase or decrease in the relative value of the U.S. dollar to other currencies would have a material effect on our consolidated financial statements.

2327

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that information required to be disclosed is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of ~~March 31,~~June 30, 2023.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the quarter ended ~~March 31,~~June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations in Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

2428

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We have, and may in the future, from time to time, become involved in litigation or other legal proceedings incidental to our business, including litigation related to intellectual property, regulatory matters, contract, advertising and other consumer claims. In the opinion of our management, reasonably possible losses in addition to the amounts accrued for any such litigation and legal proceedings are not material to our consolidated financial statements. In addition, we believe that protecting our intellectual property is essential to our business and we have in the past, and may in the future, become involved in proceedings to enforce our rights. Regardless of outcome, litigation (including the litigation ~~noted~~referenced below) can have an adverse impact on our reputation, financial condition and business, including by utilizing our resources and potentially diverting the attention of our management from the operation of our business.

For detail on certain legal proceedings, see “Note 10 - Commitments and Contingencies - Pending Legal Proceedings” included in the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1. Financial Statements of this Quarterly Report.

ITEM 1A. RISK FACTORS

An investment in our common stock involves risks. For a detailed discussion of the risks that affect our business please refer to “Item 1A. – Risk Factors" in the 2022 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

~~None.~~(a) On August 4, 2023, Olaplex, Inc. entered into a Manufacturing and Supply Agreement (the “Agreement”) with Cosway Company Inc. (“Cosway”), which supersedes the Manufacturing Services Agreement, dated January 1, 2020, by and between Olaplex, Inc. and Cosway and all amendments thereto. Pursuant to the Agreement, Cosway will manufacture, package and label certain products for Olaplex. The Agreement has an initial term of two years, unless earlier terminated in accordance with the Agreement, and automatically renews for one additional one year term, unless either party gives 180 days' notice of non-renewal. Either party may terminate the Agreement (i) with 30 days’ prior written notice in the event of a breach of the Agreement, unless such breach is cured within the 30 day notice period, (ii) if conditions constituting Force Majeure (as defined in the Agreement) exist for more than 30 consecutive days, or 60 days in any consecutive six month period, (iii) immediately in the event of insolvency, (iv) immediately or upon 30 days’ prior written notice in the event of a change in control, or (v) without cause upon 180 days' prior written notice.

The foregoing description of the Agreement is a summary and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached as Exhibit 10.1 to this Form 10-Q and is incorporated by reference herein.

(c) During the three months ended June 30, 2023, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

2529

ITEM 6. EXHIBITS


Exhibit Number						Description
3.1						Restated Certificate of Incorporation of Olaplex Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 10, 2021 (File No. 001- 40860)).
3.2						Second Amended and Restated Bylaws of Olaplex Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on January 20, 2023 (File No. 001-40860)).
10.1						~~Letter~~Manufacturing and Supply Agreement, dated ~~February 22,~~August 4, 2023, by and between Olaplex, Inc. and Cosway Company Inc. ~~(incorporated by reference to Exhibit 10.7 to the Company’'s Current Report on Form 10-K, filed on February 28, 2023 (File No. 001-40860)).~~
~~10.2#~~						~~Form of Restricted Stock Unit Agreement (Employee) under the Olaplex Holdings, Inc. 2021 Equity Incentive Plan.~~
31.1						Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2						Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1†						Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2†						Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS						Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~# Indicates a management contract or compensation plan, contract or arrangement.~~

† This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

2630

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	OLAPLEX HOLDINGS, INC.

	By:	/s/ JuE Wong
~~May 9,~~August 8, 2023		Name:	JuE Wong
		Title:	President and Chief Executive Officer
			(Principal Executive Officer)

	By:	/s/ Eric Tiziani
~~May 9,~~August 8, 2023		Name:	Eric Tiziani
		Title:	Chief Financial Officer
			(Principal Financial Officer)

2731